“The first-of-its-kind pivotal trial of an mRNA-based pandemic influenza vaccine underscores the potential of this technology to reshape how we confront emerging pathogens,” said Dr. Richard Hatchett, ...
COMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's ...
The Department of Health and Human Services had canceled hundreds of millions of dollars in funding previously committed help ...
April 21 (Reuters) - Moderna said on Tuesday the European Commission had approved its combination vaccine for the prevention ...
Moderna said on Tuesday it had started a late-stage study of its experimental bird flu vaccine in the U.S. and the UK, ...
Moderna (NasdaqGS:MRNA) plans to present Phase 1/2 data for its mRNA-4359 cancer antigen therapy combined with pembrolizumab ...
Moderna, Revolution Medicines and Zymeworks record wins in melanoma, lung and breast cancers, while BeOne swings and misses ...
Sanofi’s protein-based vaccine Nuvaxovid has conquered Moderna’s next-generation messenger RNA shot mNexspike in a ...
Moderna is the most shorted S&P 500 stock, with 17.8% short float. But its cancer pipeline, flu approval, and international ...
That raises the stakes for a second area of Moderna’s research. In a partnership with Merck, it’s been using its mRNA ...
The US Food and Drug Administration has refused to accept an application from Moderna to review its first mRNA seasonal flu vaccine, the company said Tuesday, in another setback for the technology ...
Biotech giant Moderna announced it will lay off 10% of its workforce in a move CEO Stéphane Bancel called “a difficult decision but necessary step forward,” in an internal memo sent to employees on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results